UBS has reaffirmed its 'buy' recommendation on AstraZeneca, with the target price maintained at 13,000 pence, representing a potential upside of 25% for the stock, welcoming the British pharmaceutical company's acquisition of Gracell.

According to the broker, this acquisition, announced last week, provides the group with 'a cell therapy with promising preliminary data, as well as a platform that could shorten production lead times for cell therapies'.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.